Thrombolysis for acute stroke in routine clinical practice

被引:89
作者
Bravata, DM
Kim, N
Concato, J
Krumholz, HM
Brass, LM
机构
[1] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Dept Internal Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Cardiol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA
[4] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA
关键词
D O I
10.1001/archinte.162.17.1994
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies have demonstrated that thrombolytic therapy for acute stroke can be given safely and effectively in study settings with experienced clinicians, but the patient outcomes associated with thrombolytic therapy in routine clinical practice require investigation. Objectives: To compare outcomes among patients given intravenous thrombolysis in routine clinical practice with the results of the National Institute of Neurological Disorders and Stroke rt-PA Study (NINDS cohort) and to examine whether protocol deviations are associated with adverse events. Methods: Retrospective cohort of community-based patients given thrombolysis for acute stroke from May 1, 1996, through December 31, 1998, in 16 Connecticut hospitals (Connecticut cohort). Results: Forty-two (67%) of 63 patients in the Connecticut cohort had at least 1 major protocol deviation, and 61 (97%) had major or minor protocol deviations. Overall, the in-hospital mortality was higher in the Connecticut cohort (16/63 [25%]) compared with the NINDS cohort (40/312 [13%]; P=.01). The serious extracranial hemorrhage rate was also higher for the Connecticut cohort (8/63 [13%] vs 5/312 [2%]; P=.001). Patients in the Connecticut cohort without major protocol deviations had outcomes similar to those in the NINDS cohort; however, patients in the Connecticut cohort with major protocol deviations had higher rates of in-hospital mortality (13/42 [31%] vs 40/312 [13%]; P=.002) and serious extracranial hemorrhage (7/42 [17%] vs 5/312 [2%]; P=.001). Conclusions: Protocol deviations occur commonly when thrombolytic therapy is given to stroke patients in routine clinical practice. Patients who receive thrombolysis with major protocol deviations have higher rates of in-hospital mortality and serious extracranial hemorrhage than patients in the NINDS cohort.
引用
收藏
页码:1994 / 2001
页数:8
相关论文
共 29 条
[1]   Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke - A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association [J].
Adams, HP ;
Brott, TG ;
Furlan, AJ ;
Gomez, CR ;
Grotta, J ;
Helgason, CM ;
Kwiatkowski, T ;
Lyden, PD ;
Marler, JR ;
Torner, J ;
Feinberg, W ;
Mayberg, M ;
Thies, W .
CIRCULATION, 1996, 94 (05) :1167-1174
[2]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[3]   Recommendations for the establishment of primary stroke centers [J].
Alberts, MJ ;
Hademenos, G ;
Latchaw, RE ;
Jagoda, A ;
Marler, JR ;
Mayberg, MR ;
Starke, RD ;
Todd, HW ;
Viste, KM ;
Girgus, M ;
Shephard, T ;
Emr, M ;
Shwayder, P ;
Walker, MD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (23) :3102-3109
[4]   Alteplase not yet proven for acute ischaemic stroke [J].
Bath, P .
LANCET, 1998, 352 (9136) :1238-1239
[5]   Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease [J].
Benesch, C ;
Witter, DM ;
Wilder, AL ;
Duncan, PW ;
Samsa, GP ;
Matchar, DB .
NEUROLOGY, 1997, 49 (03) :660-664
[6]   Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2109-2118
[7]   Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2119-2125
[8]   Effectiveness of t-PA in acute ischemic stroke - Outcome relates to appropriateness [J].
Buchan, AM ;
Barber, PA ;
Newcommon, N ;
Karbalai, HG ;
Demchuk, AM ;
Hoyte, KM ;
Klein, GM ;
Feasby, TE .
NEUROLOGY, 2000, 54 (03) :679-684
[9]   Why don't physicians follow clinical practice guidelines? A framewouk for improvement [J].
Cabana, MD ;
Rand, CS ;
Powe, NR ;
Wu, AW ;
Wilson, MH ;
Abboud, PAC ;
Rubin, HR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15) :1458-1465
[10]   Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke [J].
Fagan, SC ;
Morgenstern, LB ;
Petitta, A ;
Ward, RE ;
Tilley, BC ;
Marler, JR ;
Levine, SR ;
Broderick, JP ;
Kwiatkowski, TG ;
Frankel, M ;
Brott, TG ;
Walker, MD .
NEUROLOGY, 1998, 50 (04) :883-890